NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Free Cash Flow Yield on December 30, 2024: -5.35%

NewAmsterdam Pharma Company N.V. Free Cash Flow Yield is -5.35% on December 30, 2024, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

NewAmsterdam Pharma Company N.V. 52-week high Free Cash Flow Yield is -5.15% on December 17, 2024, which is 3.79% above the current Free Cash Flow Yield.
NewAmsterdam Pharma Company N.V. 52-week low Free Cash Flow Yield is -12.95% on September 25, 2024, which is -141.84% below the current Free Cash Flow Yield.
NewAmsterdam Pharma Company N.V. average Free Cash Flow Yield for the last 52 weeks is -10.27%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years